Intracellular β₂-adrenergic receptor signaling specificity in mouse skeletal muscle in response to single-dose β₂-agonist clenbuterol treatment and acute exercise

Shogo Sato · Ken Shirato · Ryosuke Mitsuhashi · Daisuke Inoue · Takako Kizaki · Hideki Ohno · Kaoru Tachiyashiki · Kazuhiko Imaizumi

Received: 7 January 2013 / Accepted: 24 February 2013 / Published online: 13 March 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract The aim of this study was to clarify the intracellular β₂-adrenergic receptor signaling specificity in mouse slow-twitch soleus and fast-twitch tibialis anterior (TA) muscles, resulting from single-dose β₂-agonist clenbuterol treatment and acute exercise. At 1, 4, and 24 h after single-dose treatment with clenbuterol or after acute running exercise, the soleus and TA muscles were isolated and subjected to analysis. The phosphorylation of p38 mitogen-activated protein kinase (MAPK) increased after single-dose clenbuterol treatment and acute exercise in the soleus muscle but not in the TA muscle. Although there was no change in the phosphorylation of Akt after acute exercise in either muscle, phosphorylation of Akt in the soleus muscle increased after single-dose clenbuterol treatment, whereas that in the TA muscle remained unchanged. These results suggest that p38 MAPK and Akt pathways play a functional role in the adaptation to clenbuterol treatment and exercise, particularly in slow-twitch muscles.

Keywords β₂-Agonist clenbuterol · Exercise · Skeletal muscle · β₂-Adrenergic receptor signaling · p38 MAPK · Akt

Introduction

β₂-Adrenergic receptor (β₂-AR) signaling in skeletal muscles plays a role in the regulation of skeletal muscle hypertrophy and metabolism. Numerous studies have shown that the selective β₂-agonist clenbuterol, a doping drug, induces skeletal muscle hypertrophy, transformation of muscle fibers, and alterations in muscle metabolic
enzymes [1, 2]. On the other hand, exercise has generally accepted to elicit multiple signals to heighten muscle protein synthesis, fiber-type switching, and mitochondrial biogenesis [3]. These adaptations to exercise are mediated in part by β2-AR activation [4]. However, the effects of β2-agonist clenbuterol and exercise on the activity of β2-AR signaling pathways in skeletal muscles are unclear. Studying β2-AR signaling in skeletal muscles is able to identify potential therapeutic applications for muscle wasting conditions such as sarcopenia, cancer cachexia, denervation, and neuromuscular diseases, aiming to attenuate the muscle wasting and associated muscle weakness, and to enhance muscle growth and repair after injury [1, 2].

It is known that β2-AR can couple to both Gαs and Gαi signaling pathways. The Gαs-adenyl cyclase (AC)-cyclic adenosine monophosphate (cAMP) pathway is the best characterized of the β2-AR signaling pathways. Phosphorylated protein kinase A (PKA) induced by cAMP regulates the activity of proteins, including cAMP response element binding protein (CREB) [1, 2]. CREB is a nuclear transcription factor that is ubiquitously expressed and has been implicated in cell proliferation, differentiation, adaptation, and survival [5]. In addition to the well-documented inhibition of AC activity, β2-AR coupling to Gαi appears to activate Gαs-dependent pathways, such as mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)-Akt signaling pathways [1, 2, 6–8]. The MAPK family, including extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 MAPK, is a ubiquitous group of signaling proteins involved in the control of cell growth, differentiation, and adaptation [9]. In particular, p38 MAPK activity in skeletal muscles is necessary for myogenic cell differentiation [10] and plays a role in glucose metabolism and energy expenditure [11, 12]. The PI3K-Akt pathway has also been implicated in protein synthesis, gene transcription, cell proliferation, and cell survival [13].

On the basis of metabolic and contractile properties and myosin heavy chain isoforms, skeletal muscle fibers can be broadly classified as type I, oxidative, slow-twitch fibers and type II, glycolytic, fast-twitch fibers. We have previously reported that the changed expression of β2-AR mRNA resulting from clenbuterol treatment for 10 days in rats [14, 15] and removing muscle loading by arthrodesis of rats for 10 days [16] is dependent upon muscle fiber type. On the basis of these findings, we hypothesized that the response of intracellular β2-AR signaling to clenbuterol treatment and exercise may differ between muscle fiber types. Therefore, in the present study, we investigated the acute effects of clenbuterol treatment and exercise on the phosphorylation of CREB, p38 MAPK and Akt in mouse skeletal muscles to clarify the intracellular signaling specificity in the typical slow-twitch soleus and fast-twitch tibialis anterior (TA) muscles.

Materials and methods

Experimental animals

Male 10-week-old C57BL/6J mice were obtained from CLEA Japan (Tokyo, Japan). These mice were housed in a temperature (23–25 °C) and humidity (50–60 %)-controlled room with a 12-h light–dark cycle. Regular rodent laboratory chow and water were available ad libitum. The experimental procedures and animal care were approved by the Committee on Animal Care, Ethics and Use, Waseda University (2011-A003), and conducted according to the Guiding Principles for the Care and Use of Animals in the Field of Physiological Sciences, the Physiological Society of Japan.

Experimental protocols

Acute experiment For the β2-agonist experiment, clenbuterol hydrochloride (Sigma, St. Louis, MO, USA) dissolved in 0.9 % NaCl solution was injected intraperitoneally (i.p.) into mice (1.0 mg/kg body weight). At 1, 4, and 24 h after treatment, the soleus and TA muscles were isolated. For the exercise experiment, because moderate exercise has been previously defined as brief (usually 15–60 min) bouts of treadmill running at 50–75 % maximum O2 consumption or 15–22 m/min [17], mice were subjected to treadmill running at 18 m/min for 1 h. At 1 (just after exercise), 4, and 24 h after exercise, the soleus and TA muscles were isolated. In all experiments, skeletal muscles were rapidly removed from mice anesthetized with isoflurane (Mylan, Tokyo, Japan), frozen in liquid nitrogen, and stored at −80 °C.

Chronic experiment Mice were subjected to 6-week voluntary exercise, β2-agonist clenbuterol treatment, or both. The animals were randomly divided into 4 groups: sedentary control (S) group, voluntary exercise-trained (EX) group, clenbuterol-treated (CL) group, and EX + CL group. EX and EX + CL mice were singly housed in stainless steel cages (height 80 mm, width 90 mm, depth 220 mm) and given 24-h access to a running wheel for 6 weeks. Wheel revolutions were counted daily and multiplied by the wheel circumference (628 mm) to obtain daily running distances. S and CL mice were singly housed in similar cages without a running wheel for 6 weeks. Further, CL and EX + CL mice were injected i.p. with clenbuterol (1.0 mg/kg body weight/day; Sigma) dissolved in 0.9 % NaCl solution. S and EX mice were also injected i.p. with the same volume of 0.9 % NaCl solution. All mice were sacrificed at 24 h after the last voluntary exercise or injection. Skeletal muscles were rapidly removed, frozen in liquid nitrogen, and stored at −80 °C.
Extraction of cytosol and membrane protein in skeletal muscles for measuring β2-AR expression

The measurement of β2-AR expression in cytosol and membrane fractions of skeletal muscles has been described previously [16, 18]. Briefly, frozen muscles were homogenized in ice-cold homogenization buffer (0.3 M KCl, 0.1 M KH2PO4, 50 mM K2HPO4, and 10 mM EDTA; pH 6.53, 1:20, w/v) containing a protease inhibitor cocktail (Thermo Fisher Scientific, Rockford, IL, USA). The homogenate was centrifuged at 100,000g for 1 h at 4°C. The resultant supernatant was collected as the cytosol fraction. The pellet was homogenized in an ice-cold solubilization buffer (homogenization buffer containing 1% Triton X-100; 1:20, w/v). After incubation for 2 h, the homogenate was centrifuged at 100,000g for 1 h at 4°C. The resultant supernatant was collected as the membrane fraction. Each protein sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride (PVDF; Millipore, Billerica, MA, USA) membrane. The membrane was blocked using phosphate-buffered saline plus Tween 20 containing 5% nonfat dry milk (w/v), and then probed with anti-β2-AR antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The bound antibody was detected using enhanced chemiluminescence (ECL; Thermo Fisher Scientific).

Reverse transcriptase-polymerase chain reaction (RT-PCR)

Total RNA extracted from skeletal muscles using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) with random primers. The product was subjected to PCR using Taq DNA polymerase (Takara Bio, Shiga, Japan) with the oligonucleotide primers as follows: β2-AR, 5′-TCT GTC TGT CTG TCT GGA TGA TG-3′ (forward), 5′-CCC ATT GTC ACA GCA GAA AGG-3′ (reverse); peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α), 5′-TGA CAT AGA GTG TGC TGC TCT G-3′ (forward), 5′-TGG TTC TGA GTG CTA AGA CCG CTG-3′ (reverse); 18S, 5′-GAG AAA CCG CTA CCA CAT CC-3′ (forward), 5′-CCC AAG ATC CAA CTA CGA GC-3′ (reverse). The PCR product was electrophoresed in 1% agarose gel (w/v) containing ethidium bromide. Fluorescence intensity was determined using the Lumino-Image Analyzer LAS-3000 System (Fuji Photo Film, Tokyo, Japan).

Western blotting analysis for β2-AR signaling molecules

Total protein from skeletal muscles was extracted using Tissue Protein Extraction Reagent (Thermo Fisher Scientific), as previously described [16]. Equal amounts of protein were separated by SDS-PAGE and transferred onto a PVDF membrane (Millipore). The membrane was blocked with 5% bovine serum albumin (w/v) in Tris-buffered saline plus Tween 20 and incubated with rabbit polyclonal antibodies against phospho-CREB (Ser133), CREB, phospho-p38 (Thr180/Tyr182), p38, phospho-Akt (Ser473), and Akt obtained from Cell Signaling Technology (Beverly, MA, USA), as well as actin antibody obtained from Santa Cruz Biotechnology; this step was followed by incubation with donkey anti-rabbit immunoglobulin G horseradish peroxidase-linked secondary antibody (GE Healthcare, Buckinghamshire, UK). Immunoreactivity was visualized using ECL (Thermo Fisher Scientific).

Statistical analysis

Results are expressed as mean ± SEM. The significance of the difference between means was assessed by the Tukey–Kramer test after significant differences between groups were established by analysis of variance. Differences were considered significant for P < 0.05.

Results

In this study, we did not observe any changes in the expression of the β2-AR protein in cytosol and membrane fractions, or in the expression of β2-AR mRNA in the soleus and TA muscles at 1–24 h after single-dose clenbuterol treatment and acute exercise (data not shown). Next, to identify β2-AR-induced signaling pathways that are potentially involved in skeletal muscle adaptation to single-dose clenbuterol treatment and acute exercise, we performed western blot analysis using phospho-specific antibodies against these molecules. We first investigated whether the phosphorylation of CREB in skeletal muscles is changed by single-dose clenbuterol treatment and acute exercise, but there was no change in the phosphorylation of CREB in the soleus and TA muscles at 1–24 h after single-dose clenbuterol treatment and acute exercise (data not shown).

We observed an increase in the mRNA expression of PGC1α, a regulator of adaptive thermogenesis, glucose metabolism, mitochondrial biogenesis, and muscle fiber type specialization, after single-dose clenbuterol treatment and acute exercise in the soleus and TA muscles (data not shown). It has been reported that exercise stimulates PGC1α transcription in skeletal muscles through the activation of the p38 MAPK pathway [19] and β2-AR [4]. These findings strongly suggest that activation of the p38 MAPK pathway mediated by β2-AR plays a key role in clenbuterol- and exercise-induced skeletal muscle...
adaptation. Therefore, we next investigated whether the phosphorylation of p38 MAPK in skeletal muscles is changed by single-dose clenbuterol treatment and acute exercise. The phosphorylation of p38 MAPK in the soleus muscle was significantly increased, to 580 and 460 %, at 1 and 4 h, respectively, after single-dose clenbuterol treatment (Fig. 1a), whereas that in the TA muscle remained unchanged, to 170 % (P = 0.14) and 160 % (P = 0.19), at 1 and 4 h, respectively, after single-dose clenbuterol treatment (Fig. 1a). On the other hand, the phosphorylation of p38 MAPK in the soleus muscle was significantly increased, to 360 and 240 %, at 1 and 4 h, respectively, after acute exercise in the soleus muscle, whereas that in the TA muscle remained unchanged (Fig. 1b). Furthermore, as shown in Fig. 1, a slower migrating band was observed with the phospho-specific antibody in the soleus muscle from clenbuterol-treated and exercised mice, which is indicative of phosphorylated p38γ subunits [21].

Next, we investigated whether the phosphorylation of Akt in skeletal muscles is changed by single-dose clenbuterol treatment and acute exercise. The phosphorylation of Akt was significantly increased, to 360 and 240 %, at 1 and 4 h, respectively, after clenbuterol treatment in the soleus muscle, whereas that in the TA muscle remained unchanged (Fig. 2a). In contrast to clenbuterol treatment, we did not find any changes in the phosphorylation of Akt after acute exercise in the soleus and TA muscles (Fig. 2b).

Discussion

In the present study, we observed an increase in the phosphorylation of p38 MAPK after single-dose clenbuterol treatment and acute exercise on the activation of ERK1/2, members of MAPK family, to a greater extent in the TA muscle than in the soleus muscle [24]. In addition, ablation of ERK1/2 had little effect on clenbuterol-induced slow-twitch fiber-specific gene expression, whereas it inhibited clenbuterol-induced fast-twitch fiber-specific gene expression [24]. These findings suggest that ERK1/2 is necessary for the hypertrophic process in fast-twitch muscles. On the other hand, some studies have also highlighted the possibility that the activation of p38 MAPK may inhibit ERK1/2 phosphorylation [25, 26]. It is possible that the lower level of ERK1/2 activation was due to the higher level of p38 MAPK activation in the soleus muscle (Fig. 1), considering the antagonizing action of p38 MAPK on ERK1/2 activation. Daaka et al. [6] demonstrated in the HEK293 cell line the model for β2-AR-mediated G-protein switching to activate MAPK; phosphorylation of MAPK by the β2-AR proceeds through receptor coupling to Gz, and activation of PKA. Activated PKA phosphorylates the β2-AR leading to receptor coupling to, and activation of, Gz, and then Gβγ released from the Gz-coupled β2-AR activates MAPK in a Src- and Ras-dependent pathway. The in vitro cell culture model suggests the possibility that β2-agonist
clenbuterol-induced receptor phosphorylation through the activation of PKA may progress in slow-twitch soleus muscle, compared to fast-twitch TA muscle, which is responsible for the increase in the phosphorylation of p38 MAPK after clenbuterol treatment to a much greater extent in the soleus muscle than the TA muscle.

Our study also demonstrated that the phosphorylation of Akt was significantly increased after clenbuterol treatment in the soleus muscle, whereas that in the TA muscle remained unchanged (Fig. 2a). Kline et al. [27] also observed an increase in the phosphorylation of Akt in rat fast-twitch muscles after single-dose and long-term (9 days) treatment with clenbuterol (3.0 mg/kg body weight). Likewise, Gonçalves et al. [28] reported that single-dose clenbuterol treatment increased the phosphorylation of Akt in rat fast-twitch muscles without changing that in rat slow-twitch muscles. In contrast to rats, single-dose treatment with clenbuterol in mice was found to increase the phosphorylation of Akt in the soleus muscle [28]. We found no change in the phosphorylation of Akt in the soleus and TA muscles after 6 weeks of clenbuterol treatment (1.0 mg/kg body weight/day) (data not shown). These findings indicate that the effect of clenbuterol on the phosphorylation of Akt differs between muscle fiber types and species, and is dependent upon the dose and duration of clenbuterol treatment.

We did not find any changes in the phosphorylation of Akt after acute exercise in the soleus and TA muscles (Fig. 2b). Some studies have shown that exercise increases the phosphorylation and activity of Akt in rat slow-twitch
and fast-twitch muscles [29, 30], whereas others have observed no such effect [31, 32]. Passive stretch and electric stimulation of rat skeletal muscles was also found to increase the phosphorylation and activity of Akt in fast-twitch muscles, but not slow-twitch muscles [29, 32], whereas no such effect was observed following muscle contraction in rat skeletal muscles [31]. These findings indicate that the phosphorylation level of Akt differs between experimental models in relation to the intensity of exercise and contraction. Further experiments are needed to confirm this observation.

Specifically, in vitro cell culture experiments have revealed that the \( \text{G}_{\alpha_i} \)-linked \( \text{G}_{\beta\gamma} \) subunits activate the PI3K-Akt signaling pathway [7, 8, 33, 34]. Multiple skeletal muscle Akt pathways are involved not only in the signaling pathways responsible for muscle hypertrophy but also in the inhibition of signaling pathways responsible for muscle atrophy, which are activated following \( \beta_2 \)-AR stimulation, and these lead predominantly to hypertrophy in fast-twitch muscle [27]. Therefore, these studies have implicated that the \( \text{G}_{\beta\gamma} \)-PI3K-Akt signaling pathway has important roles in fast-twitch skeletal muscle hypertrophy. However, the increase in the phosphorylation of Akt following clenbuterol treatment was observed to a greater degree in slow-twitch soleus muscle than in fast-twitch TA muscle (Fig. 2a), which appears inconsistent with the finding that \( \beta_2 \)-AR stimulation induced hypertrophy preferentially in fast-twitch muscles [2, 14, 15]. These results
indicate the possibility that activation of Akt in slow-twitch muscles may account not for anabolic adaptation but for metabolism adaptation. For instance, Akt is known to be an important signaling molecular in the insulin signaling pathways [35]. The finding that β2-agonist clenbuterol administration increases blood glucose and insulin concentrations [36] could be responsible for the promotion of Akt phosphorylation in skeletal muscles, where it is accepted as the best stored tissue of glycogen. Further studies are needed to clarify this hypothesis.

In conclusion, the present study shows the intracellular β2-AR signaling specificity in mouse skeletal muscles in response to single-dose clenbuterol treatment and acute exercise. The current findings suggest that p38 MAPK and Akt pathways play a functional role in the adaptation to clenbuterol treatment and exercise, particularly in slow-twitch muscles. In particular, the β2-agonists and intracellular β2-AR signaling have important clinical significance for enhancing muscle repair and restoring muscle function after muscle atrophy. Thus, this scientific evidence about intracellular β2-AR signaling in skeletal muscle could contribute to the identification of new therapeutic targets for attenuating muscle wasting and to the eradication of sports doping.

Acknowledgments The present study was supported in part by Research Fellowships from the Japan Society for Promotion of Science for Young Scientists (2010–2011; S. Sato), and a Grant-in-Aid from global center of excellence (COE) program, Graduate School of Sport Sciences, Waseda University (2009–2013; K. Imaizumi) of the Ministry of Education, Culture, Sports, Science and Technology, Japan, and a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Sciences and Technology (2012–2013, 24650404; K. Imaizumi).

Conflict of interest The authors declare that there are no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Lynch GS, Ryall JG (2008) Role of β-adrenoceptor signaling in skeletal muscle: implication for muscle wasting and disease. Physiol Rev 88:729–767
2. Sato S, Shirato K, Tachiyashiki K, Imaizumi K (2011) Muscle plasticity and β2-adrenergic receptors: adaptive responses of β2-adrenergic receptor expression to muscle hypertrophy and atrophy. J Biomed Biotech 2011:729598
3. Timmons JA (2011) Variability in training-induced skeletal muscle adaptation. J Appl Physiol 110:846–853
4. Miura S, Kawanaka K, Kai Y, Tamura M, Goto M, Shiuchi T, Minokoshi Y, Ezaki O (2007) An increase in murine skeletal muscle peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1-α) mRNA in response to exercise is mediated by β-adrenergic receptor activation. Endocrinology 148:3441–3448
5. Mary B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599–609
6. Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88–91
7. Murga C, Laguninge L, Wetzker R, Cuadrado A, Gutkind JS (1998) Activation of Akt/protein kinase B by G protein-coupled receptors. A role for α and β subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase γ. J Biol Chem 273:19080–19085
8. Murga C, Fukuhara S, Gutkind JS (2000) A novel role for phosphatidylinositol 3-kinase β in signaling from G protein-coupled receptors to Akt. J Biol Chem 275:12069–12073
9. Cowan KI, Storey KB (2003) Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol 206:1107–1115
10. Zetser A, Gredinger E, Bernal E (1999) p38 Mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J Biol Chem 274:5193–5200
11. Niu W, Huang C, Nawaz Z, Levy M, Somwar R, Li D, Bilan PJ, Klip A (2003) Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J Biol Chem 278:17953–17962
12. Puisieux P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARGamma coactivator-1. Mol Cell 8:971–982
13. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Baufrein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014–1019
14. Sato S, Nomura S, Kawano F, Tanihata J, Tachiyashiki K, Imaizumi K (2008) Effects of the β2-agonist clenbuterol on β1- and β2-adrenoceptor mRNA expression of rat skeletal and left ventricle muscles. J Pharmacol Sci 107:393–400
15. Sato S, Nomura S, Kawano F, Tanihata J, Tachiyashiki K, Imaizumi K (2010) Adaptive effects of the β2-agonist clenbuterol on expression of β2-adrenoceptor mRNA in rat fast-twitch fiber-type muscles. J Physiol Sci 60:119–127
16. Sato S, Suzuki H, Tsujimoto H, Shirato K, Tachiyashiki K, Imaizumi K (2011) Casted-immobilization downregulates glucocorticoid receptor expression in rat slow-twitch soleus muscle. Life Sci 89:962–967
17. Schefer V, Talan MI (1996) Oxygen consumption in adult and AGED C57BL/6J mice during acute treadmill exercise of different intensity. Exp Gerontol 31:387–392
18. Sato S, Shirato K, Tachiyashiki K, Imaizumi K (2011) Synthetic glucocorticoid, dexamethasone regulates the expressions of β2-adrenoceptor and glucocorticoid receptor mRNAs but not proteins in slow-twitch soleus muscle of rats. J Toxicol Sci 36:479–486
19. Akimoto T, Pohnert SC, Li P, Zhang M, Gumbs C, Rosenberg PB, Williams RS, Yan Z (2005) Exercise stimulates pgc1-α transcription in skeletal muscle through activation of the p38 MAPK pathway. J Biol Chem 280:19587–19593
20. Pogorzelski AR, Geng T, Li P, Yin X, Lira VA, Zhang M, Chi JT, Yan Z (2009) p38γ mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice. PLoS ONE 4:e7934
21. Foster WH, Tidball JG, Wang Y (2012) p38γ activity required for maintenance of slow skeletal muscle size. Muscle Nerve 45:266–273
22. Carlson CJ, Fan Z, Gordon SE, Booth FW (2001) Time course of the MAPK and PI3-kinase response within 24 h of skeletal muscle overload. J Appl Physiol 91:2079–2087
23. Kitaura T, Tsunekawa N, Hatta H (2001) Decreased monocarboxylate transporter 1 in rat soleus and EDL muscles exposed to clenbuterol. J Appl Physiol 91:85–90
24. Shi H, Zeng C, Ricome A, Hannon KM, Grant AL, Gerrard DE (2007) Extracellular signal-regulated kinase pathway is differentially involved in β-agonist-induced hypertrophy in slow and fast muscles. Am J Physiol Cell Physiol 292:C1681–C1689
25. Bianchini L, L’Allemain G, Pouyssegur J (1997) The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors. J Biol Chem 272:271–279
26. Widmann C, Gibson S, Jarpe MB, Johnson GL (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79:143–180
27. Kline WO, Panaro FJ, Yang H, Bodine SC (2007) Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol 102:740–747
28. Gonçalves DA, Silveira WA, Lira EC, Graça FA, Paula-Gomes S, Zanon NM, Kettelhut IC, Navegantes LC (2012) Clenbuterol suppresses proteosomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt. Am J Physiol Endocrinol Metab 302:E123–E133
29. Sakamoto K, Aschenbach WG, Hirshman MF, Goodyear LJ (2003) Akt signaling in skeletal muscle: regulation by exercise and passive stretch. Am J Physiol Endocrinol Metab 285:E1081–E1088
30. Gosmanov AR, Nordtvedt NC, Brown R, Thomason DB (2002) Exercise effects on muscle β-adrenergic signaling for MAPK-dependent NKCC activity are rapid and persistent. J Appl Physiol 93:1457–1465
31. Sherwood DJ, Dufresne SD, Markuns JF, Cheatham B, Moller DE, Aronson D, Goodyear LJ (1999) Differential regulation of MAP kinase, p70S6K, and Akt by contraction and insulin in rat skeletal muscle. Am J Physiol Endocrinol Metab 276:E870–E878
32. Nader GA, Esser KA (2001) Intracellular signaling specificity in skeletal muscle in response to different modes of exercise. J Appl Physiol 90:1936–1942
33. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R (1997) Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. Science 275:394–397
34. Schmidt P, Holsboer F, Spengler D (2001) β2-Adrenergic receptors potentiate glucocorticoid receptor transactivation via G protein βγ-subunits and the phosphoinositide 3-kinase pathway. Mol Endocrinol 15:553–564
35. Zaid H, Antonescu CN, Randhawa VK, Klip A (2008) Insulin action on glucose transporters through molecular switches, tracks and tethers. Biochem J 413:201–215
36. Edwards DJ, Virji MA (1990) Hypoaminoacidemia caused by imipramine but not by clenbuterol is dissociable from hyperglycemia and hyperinsulinemia. Life Sci 47:13–18